What do systematic reviews say?

Prebiotic vs another prebiotic

The review found no eligible studies for this question.

• Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prebiotic vs probiotic

The review found no eligible studies for this question.

• Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prebiotic vs placebo or no treatment

The review found no eligible studies for this question.

• Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Synbiotic vs prebiotic

The review found no eligible studies for this question.

• Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs placebo

• Metformin for preventing the progression of chronic kidney disease 2024 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 100 participants
  Very low

Renin‐angiotensin system inhibition vs supportive treatment

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 168 participants
  Moderate

Tonsillectomy plus standard care vs usual care

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 69 participants
  Low

Renin‐angiotensin system inhibition vs placebo or no treatment

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 199 participants
  Moderate

Aldosterone antagonists vs diuretics

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 139 participants
  Very low

Aldosterone antagonists vs calcium channel blockers

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Aldosterone antagonists vs ACEi or ACEi plus ARB

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 465 participants
  Very low

Aldosterone antagonists vs nitrate

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 1193 participants
  Very low

Probiotics vs placebo or no treatment

• Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Very low

Renin‐angiotensin system inhibition vs supportive treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tonsillectomy plus standard care vs usual care

Tonsillectomy plus standard care may leads to lower relapse of proteinuria compared with standard care (low certainty).

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  RR 0.7 [0.57, 0.85]
  1 study · 73 participants
  Low

Renin‐angiotensin system inhibition vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Renin‐angiotensin system inhibition vs supportive treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tonsillectomy plus standard care vs usual care

Tonsillectomy plus standard care may leads to higher remission of proteinuria compared with standard care (low certainty).

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  RR 1.9 [1.45, 2.47]
  2 studies · 143 participants
  Low